Latest news with #CBD
Daily Record
3 hours ago
- Health
- Daily Record
Debenhams offering £305 worth of luxury anti-ageing skincare for just £41
Calling all skincare buffs, as this deal is not to be missed. Skincare buffs looking to bag some new products are in for a treat. Debenhams is offering a luxury branded bundle at 86 percent less than its RRP. London Botanical Laboratories, famed for offering natural, clean products, has earned a glowing reputation from beauty fans who say its products have left their skin looking "brighter" and "hydrated." However, like many luxury brands, its products can come with a high price-tag, with this Renew & Glow Skincare Set being worth a staggering £305 in total. Luckily, Debenhams shoppers can bag it for just £41.25 - saving over £263 on premium anti-ageing skincare. Designed to target skin texture, tone and the signs of ageing, this bundle comes complete with two sets from the skincare brand - both containing a moisturiser and a serum each. Up first is the Brightening Vitamin C Set that features the firm's Vitamin C + CBD Serum that would set you back £85 alone for the 30ml included. This "lightweight" formula is packed with anti-oxidants and hyaluronic acid to target sun pigmentation, acne marks and uneven skin tone. Renew & Glow Skincare Set £305 £41.25 Debenhams Buy here Product Description There's also the Vitamin C + CBD The Pro-Glow Fresh Vit C Day Cream, worth £85, that boats all the same ingredients, alongside an "uplifting" scent to leave your skin radiant and hydrated. To help smooth out fine lines and target the appearance of wrinkles, the final two products included in the bundle are from the firm's Bakuchiol Renewal Set that features the Bakuchiol + CBD Serum (30ml) and the Bio-Retinol Ultimate 8-Hour Renew Night Cream (50ml), both worth £89 each. Both the bakuchiol serum and night cream have been infused with a bio-retinol that is said to be effective, but also gentle, on the appearance of fine lines and wrinkles, while the addition of a three plum extract makes it a "unique" addition to the market. Shoppers maybe looking to try out an assortment of different brands for less, there is Boots' £40 Pamper Beauty Box that is packed with over £156 worth of products from Sundae, BYOMA, Bloom & Blossom and Liz Earle. Meanwhile, Superdrug is offering this Dr. Eve_Ryouth Ultimate Wrinkle Filler Face & Eyes Set, worth £179, for just £24.99, saving beauty buffs an incredible 86 percent on proven anti-ageing skincare. Join the Daily Record WhatsApp community! Get the latest news sent straight to your messages by joining our WhatsApp community today. You'll receive daily updates on breaking news as well as the top headlines across Scotland. No one will be able to see who is signed up and no one can send messages except the Daily Record team. All you have to do is click here if you're on mobile, select 'Join Community' and you're in! If you're on a desktop, simply scan the QR code above with your phone and click 'Join Community'. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. To leave our community click on the name at the top of your screen and choose 'exit group'. If you're curious, you can read our Privacy Notice. As for the Renew & Glow Skincare Set, Debenhams shoppers have left it glowing reviews hailing it as a "bargain" deal that has provided them with "effective" products for less. One delighted customer wrote: "Great products and price. A real bargain: saved £££s." A second delighted beauty fan said: "Extremely effective product highly recommended, pleased with results." Beauty deal of the week It's almost Father's Day, and are you in need of some gift inspiration? If you don't want to buy a last minute gift, then we have you covered, as a bottle of aftershave is always a good shout and Debenhams has just cut the Yves Saint Laurent L'Homme Eau De Toilette from £92 to just £55.20 for a large 100ml bottle. There is also a smaller 60ml bottle that is a bit cheaper, with the price being reduced by 37 per cent from £68 to £43. Since reviews say it "stands out from the crowd", it's a deal worth bagging for dad. Launched in 2006, this YSL fragrance has been described as "a fragrance for the urban and charismatic 21st century male". For the guy in your life who likes to smell a little different, then this is the bottle to reach for. It opens on sparkling notes of bergamot, zesty cedarwood and Chinese ginger that has been met with the middle notes of violet leaves and basil flowers, offering a floral and spicy contrast. It is said to end on base notes of sandalwood, Virginia cedar wood and Haitian vetiver to "highlight this charismatic and magnetic fragrance." Those who want to stand out from the crowd will appreciate the YSL L'Homme Eau De Toilette, as it has earned a 4.7 rating from Debenhams fragrance buffs who have said it is "unusual" and "always gets compliments." One positive review read: "An unusual and outstanding men's perfume! What an interesting fresh yet a hint of spice men's perfume! It's different. Stands out from the crowd. Purchase the Yves Saint Laurent L'Homme Eau De Toilette (100ml) in the Debenhams sale here. Meanwhile, on the London Botanical Laboratories website, there are many other positive reviews for each product included, as one said of the vitamin C set: "I love the texture of this moisturizer bought this with the serum and the entire set is truly amazing." While another said of the bakuchiol serum: "The blend of Bakuchiol and CBD has visibly improved my skin's texture and reduced the appearance of fine lines. This serum is now my go-to, and I can't recommend it enough for a more youthful and radiant look." As of writing, we could not find any negative reviews for the Renew & Glow Skincare Set, adding to its exclusive status. here.
Daily Mirror
a day ago
- Entertainment
- Daily Mirror
Heartbreaking reality behind Jason Isaacs and Gillian Anderson's The Salt Path
The Salt Path stars Jason Isaacs and Gillian Anderson as a couple who embark on a 630-mile walk after suffering a number of life-changing setbacks - but is the new movie based on a true story? The new film, The Salt Path, narrates an extraordinary and uplifting tale about a couple who undertake a challenging journey after facing a series of severe hardships. Raynor and Moth Winn – portrayed in the film by Gillian Anderson and Jason Isaacs – found themselves homeless in the same week that Moth was diagnosed with a rare terminal illness, given a maximum of five years to live. Instead of succumbing to these adversities and surrendering, the duo decided to traverse the South West Coast Path, an experience that proved to be incredibly rejuvenating, as they encountered the generosity of strangers along their journey. Indeed, the film is based on the real-life story of the couple Raynor and Moth Winn, as recounted by Raynor in her memoir bearing the same title. It follows their 630-mile coastal journey along the South West Coast Path after being evicted from the farm they called home. In the same week they found themselves without a roof over their heads in August 2013, Moth was dealt a devastating blow with a terminal diagnosis of Corticobasal Degeneration (CBD). Raynor, upon discovering a Southwest Coast Path guidebook, felt it was their final shot at freedom. Despite Moth's health deteriorating each day at the outset of their journey, his condition remarkably began to improve as they continued their walk – and astonishingly, he's still with us over a decade later, having been given no more than five years to live at the time of his diagnosis. The screenplay, penned by Rebecca Lenkiewicz, remains faithful to the true events of Raynor and Moth's remarkable tale, albeit with minor creative tweaks. Raynor shared: "The final script was beautiful, capturing the essence of the original story while taking it forward on a powerful new journey." Gillian and Jason are no strangers to portraying real-life figures, from Margaret Thatcher to Cary Grant. However, in an exclusive chat with the duo divulged that embodying individuals away from the public gaze presented a unique set of challenges. "It's definitely less stressful, less pressure," Anderson elaborated. "You want to, obviously, do right by them and to be respectful in your impersonation. But at the same time it's not quite as intense as doing somebody who's in front of the public eye as much as say a Thatcher or Emily Maitlis or something. "Because the public aren't going to go, 'Well, that's not like them,'" Isaacs concurred. "But also, we really like them. Ray and Moth are amazing people, and their story is so inspiring. The books are so successful, and rightfully so, because they contain messages of such hope and belief and compassion." "And so you not only want them to feel glad that we're doing it, but you want the audience to feel what we felt when we met them, when we read their stories and to be as moved and inspired by their story." "When it came to meeting the real-life Raynor and Moth, Isaacs clarified that he was less focused on mimicking mannerisms and more interested in understanding what made the couple tick. I'm never gonna be as tall, handsome, smiley [as Moth], he's just an extraordinary man," he admitted. "So I just wanted to know, 'What is it inside him?' One of the things I got when I met him is the sign that he wanted everyone else to feel comfortable." "He makes a joke of everything, even when he was talking to me at great length about this tremendous indignity and terror of his condition and where it will naturally end, he wanted to make me feel at ease. So he made me laugh all the time about it. That's a quality I recognised and could walk away with," she reflected. Anderson shared that listening to Raynor narrate the audio book of her memoir was instrumental in helping her embody the character. "It felt like I was properly immersed in her rhythm and her personality," she expressed. "Her accent is quite unusual. Both of their accents are quite unusual. And I found it very challenging. So I think at the end of the day, you kind of choose what feels organic and isn't forced, and hope that that's enough of an impression that they can recognise themselves."
Associated Press
2 days ago
- Business
- Associated Press
Your CBD Store® and Independent Business Owners Oppose SB 3: A Call to Action for Texas Residents
Sunmed™ | Your CBD Store® asks Texas Governor Greg Abbott to Veto Senate Bill 3 AUSTIN, Texas, May 30, 2025 /PRNewswire/ -- Sunmed™ | Your CBD Store® stands in firm opposition to Texas Senate Bill 3 (SB 3), which threatens the livelihood of thousands of small and independent Texas merchants and business owners and denies access to a wide range of wellness and therapeutic products. This Bill, if signed into law, will have devastating consequences for Texas's small business community, including the loss of over 53,000 jobs and the closure of 8,000 businesses. Key Concerns: Massive Job Loss SB 3 jeopardizes more than 53,000 jobs in the Texas hemp industry, directly threatening the livelihoods of families across the state. Severe Economic Impact The Bill's economic repercussions are extensive and disproportionately harmful to small and independently owned businesses that depend on the sale and merchandising of hemp products. A fiscal note from the Legislative Budget Board (LBB) projects a net negative impact of $19.27 million to general revenue-related funds for the biennium ending August 31, 2027. These losses are expected to increase annually, reaching an estimated $11.69 million by 2030. These projections are considered conservative, and the actual impact is expected to be significantly greater. (Source: Texas Senate Bill 3: Dan Patrick's Ban on All THC Products - Texas Policy Research ) Reduced Consumer Choice SB 3 does not reflect the interests of Texas residents, who have consistently voiced strong support for accessible and responsibly regulated hemp products. Public hearings have included extensive testimony opposing the Bill, highlighting overwhelming community support. Overly Restrictive Regulations The Bill effectively amounts to an industry-wide ban by limiting permissible hemp-derived consumables to only isolated forms of CBD and CBG. These limitations exclude a variety of THC-free, broad-spectrum products that consumers rely on, and force businesses to develop entirely new product lines to remain compliant. Unsustainable Costs for Small Businesses SB 3 imposes burdensome licensing fees of $20,000 annually for retailers and $10,000 per year plus $500 per product for manufacturers. These fees place an undue financial strain on small businesses, threatening their sustainability. Call to Action We urge all Texans to oppose SB 3. Contact Governor Abbott and request that he veto this harmful legislation: Sunmed™ | Your CBD Store® stands with small businesses and the Texas communities they serve. We believe in protecting consumer access to safe, effective hemp products and supporting the local entrepreneurs who provide them. Join us in defending our industry, our economy, and our right to choose. Contact Patrick Shatzer Sunmed l Your CBD Store [email protected] About Sunmed™ | Your CBD Store® Sunmed | Your CBD Store, an affiliate of Sunflora, Inc., is the largest hemp retailer in the United States and the exclusive home of award-winning, hemp-derived Sunmed products. With 300+ nationwide locations across 42 states, the brand offers a premium in-store customer experience with access to 150+ nonpharmaceutical wellness formulas, including clinically proven sleep gummies, pain relief topicals, USDA-organic oil tinctures, and CBD for pets. Through in-store education, community involvement, and groundbreaking clinical research, Sunmed strives to empower modern wellness and enhance people's lives with natural science-backed products. Learn more at View original content to download multimedia: SOURCE Sunmed
Yahoo
2 days ago
- Business
- Yahoo
Australia Legal Cannabis Market Forecast Report 2025-2030 - Surge in Demand for Low-Dose CBD and OTC Access
The main market opportunities in the Australian legal cannabis sector are driven by supportive regulatory frameworks, increased medical cannabis prescriptions, and a rising demand for low-dose CBD products. Domestic production and diversified product offerings further enhance growth, positioning Australia as a key cannabis innovation hub. Australian Legal Cannabis Market Dublin, May 30, 2025 (GLOBE NEWSWIRE) -- The "Australia Legal Cannabis Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to offering. The Australia Legal Cannabis Market was valued at USD 126.32 million in 2024 and is expected to reach USD 420.33 million by 2030, rising at a CAGR of 22.16% This growth is fueled by progressive legislative developments, increasing medical awareness, and broader access initiatives for therapeutic cannabis. Federal and state-level regulatory advancements are fostering a more organized and transparent cannabis sector. The market is experiencing a notable rise in medical cannabis prescriptions, driven by its application in treating chronic pain, anxiety, sleep disorders, and other conditions. Domestic production is also gaining traction as companies invest in localized cultivation and processing infrastructure, aiming to enhance supply chain efficiency and reduce reliance on imports. Support from healthcare providers, coupled with growth in clinical education and research, continues to boost adoption across medical fields. Meanwhile, the industry is evolving through diversification in product offerings - such as oils, capsules, and topicals - and the integration of digital health platforms, positioning Australia as a key regional hub for cannabis innovation and export. Favorable Regulatory Environment and Policy Support A supportive regulatory framework and comprehensive policy measures are key enablers of growth in the Australia Legal Cannabis Market. Since the 2016 legalization of medicinal cannabis, the Australian government has implemented structured systems allowing licensed cultivation, production, and distribution. Agencies like the Therapeutic Goods Administration (TGA) and the Office of Drug Control (ODC) oversee pathways such as the Special Access Scheme (SAS) and the Authorised Prescriber Scheme, facilitating legal, controlled patient access to cannabis treatments when conventional methods fall short. Recent developments, including the reclassification of low-dose CBD as a Schedule 3 substance, reflect a progressive stance aimed at increasing accessibility. Though no products have yet gained OTC approval, this shift highlights the government's intent to broaden access to non-psychoactive cannabis applications. These changes not only enhance patient reach but also encourage foreign investment, support pharmaceutical innovation, and elevate Australia's standing as a regulated and export-ready cannabis market. High Costs of Production and Patient Access The Australia Legal Cannabis Market faces significant hurdles due to the high costs associated with producing pharmaceutical-grade cannabis and the barriers these costs create for patient access. Compliance with strict quality and safety standards necessitates large investments in advanced cultivation technology and quality assurance systems. These costs inflate retail prices, placing a financial burden on patients - particularly since medical cannabis is not covered under the Pharmaceutical Benefits Scheme (PBS). As a result, patients must rely on out-of-pocket payments, limiting affordability and reducing uptake, especially among those needing ongoing treatment. The lack of insurance coverage further exacerbates the issue. Additionally, navigating regulatory processes such as the SAS and securing prescriptions from qualified practitioners can be complex and time-consuming. Limited awareness among medical professionals about cannabis therapies adds to access difficulties. Together, these financial and procedural barriers hinder the market's growth potential and restrict the widespread adoption of cannabis-based treatments. Surge in Demand for Low-Dose CBD and OTC Access A growing consumer interest in wellness and plant-based alternatives is fueling demand for low-dose cannabidiol (CBD) products in the Australian market. This trend gained momentum after the Therapeutic Goods Administration (TGA) reclassified low-dose CBD (up to 150 mg/day) as a Schedule 3 substance, potentially allowing over-the-counter availability without a prescription. While no such products have yet received approval, the regulatory shift signals expanded access to cannabis-derived wellness products aimed at managing mild ailments like anxiety and sleep disorders. This evolving preference is prompting companies to invest in the research and development of clinically validated, standardized formulations that comply with strict safety and efficacy guidelines. As consumers increasingly favor self-directed health solutions, the market is witnessing heightened innovation and competition among players aiming to secure a share in this emerging OTC segment. Report Scope Key Market Players: Cann Group Limited Zelira Therapeutics AusCann Group Holdings Ltd. Bod Australia Althea Group ECOFIBRE Botanix Pharmaceuticals EPSILON Little Green Pharma Incannex Australia Legal Cannabis Market, By Source: Hemp Marijuana Australia Legal Cannabis Market, By Derivatives: CBD THC Others Australia Legal Cannabis Market, By Cultivation: Indoor Cultivation Greenhouse Cultivation Outdoor Cultivation Australia Legal Cannabis Market, By End Use: Industrial Use Medical Use Recreational Use Australia Legal Cannabis Market, By Region: Victoria & Tasmania Queensland Western Australia Northern Territory & Southern Australia Australia Capital Territory & New South Wales Key Attributes: Report Attribute Details No. of Pages 84 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $126.32 Million Forecasted Market Value (USD) by 2030 $420.33 Million Compound Annual Growth Rate 22.1% Regions Covered Australia For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Australian Legal Cannabis Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Australia Legal Cannabis Market Forecast Report 2025-2030 - Surge in Demand for Low-Dose CBD and OTC Access
The main market opportunities in the Australian legal cannabis sector are driven by supportive regulatory frameworks, increased medical cannabis prescriptions, and a rising demand for low-dose CBD products. Domestic production and diversified product offerings further enhance growth, positioning Australia as a key cannabis innovation hub. Australian Legal Cannabis Market Dublin, May 30, 2025 (GLOBE NEWSWIRE) -- The "Australia Legal Cannabis Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to offering. The Australia Legal Cannabis Market was valued at USD 126.32 million in 2024 and is expected to reach USD 420.33 million by 2030, rising at a CAGR of 22.16% This growth is fueled by progressive legislative developments, increasing medical awareness, and broader access initiatives for therapeutic cannabis. Federal and state-level regulatory advancements are fostering a more organized and transparent cannabis sector. The market is experiencing a notable rise in medical cannabis prescriptions, driven by its application in treating chronic pain, anxiety, sleep disorders, and other conditions. Domestic production is also gaining traction as companies invest in localized cultivation and processing infrastructure, aiming to enhance supply chain efficiency and reduce reliance on imports. Support from healthcare providers, coupled with growth in clinical education and research, continues to boost adoption across medical fields. Meanwhile, the industry is evolving through diversification in product offerings - such as oils, capsules, and topicals - and the integration of digital health platforms, positioning Australia as a key regional hub for cannabis innovation and export. Favorable Regulatory Environment and Policy Support A supportive regulatory framework and comprehensive policy measures are key enablers of growth in the Australia Legal Cannabis Market. Since the 2016 legalization of medicinal cannabis, the Australian government has implemented structured systems allowing licensed cultivation, production, and distribution. Agencies like the Therapeutic Goods Administration (TGA) and the Office of Drug Control (ODC) oversee pathways such as the Special Access Scheme (SAS) and the Authorised Prescriber Scheme, facilitating legal, controlled patient access to cannabis treatments when conventional methods fall short. Recent developments, including the reclassification of low-dose CBD as a Schedule 3 substance, reflect a progressive stance aimed at increasing accessibility. Though no products have yet gained OTC approval, this shift highlights the government's intent to broaden access to non-psychoactive cannabis applications. These changes not only enhance patient reach but also encourage foreign investment, support pharmaceutical innovation, and elevate Australia's standing as a regulated and export-ready cannabis market. High Costs of Production and Patient Access The Australia Legal Cannabis Market faces significant hurdles due to the high costs associated with producing pharmaceutical-grade cannabis and the barriers these costs create for patient access. Compliance with strict quality and safety standards necessitates large investments in advanced cultivation technology and quality assurance systems. These costs inflate retail prices, placing a financial burden on patients - particularly since medical cannabis is not covered under the Pharmaceutical Benefits Scheme (PBS). As a result, patients must rely on out-of-pocket payments, limiting affordability and reducing uptake, especially among those needing ongoing treatment. The lack of insurance coverage further exacerbates the issue. Additionally, navigating regulatory processes such as the SAS and securing prescriptions from qualified practitioners can be complex and time-consuming. Limited awareness among medical professionals about cannabis therapies adds to access difficulties. Together, these financial and procedural barriers hinder the market's growth potential and restrict the widespread adoption of cannabis-based treatments. Surge in Demand for Low-Dose CBD and OTC Access A growing consumer interest in wellness and plant-based alternatives is fueling demand for low-dose cannabidiol (CBD) products in the Australian market. This trend gained momentum after the Therapeutic Goods Administration (TGA) reclassified low-dose CBD (up to 150 mg/day) as a Schedule 3 substance, potentially allowing over-the-counter availability without a prescription. While no such products have yet received approval, the regulatory shift signals expanded access to cannabis-derived wellness products aimed at managing mild ailments like anxiety and sleep disorders. This evolving preference is prompting companies to invest in the research and development of clinically validated, standardized formulations that comply with strict safety and efficacy guidelines. As consumers increasingly favor self-directed health solutions, the market is witnessing heightened innovation and competition among players aiming to secure a share in this emerging OTC segment. Report Scope Key Market Players: Cann Group Limited Zelira Therapeutics AusCann Group Holdings Ltd. Bod Australia Althea Group ECOFIBRE Botanix Pharmaceuticals EPSILON Little Green Pharma Incannex Australia Legal Cannabis Market, By Source: Hemp Marijuana Australia Legal Cannabis Market, By Derivatives: CBD THC Others Australia Legal Cannabis Market, By Cultivation: Indoor Cultivation Greenhouse Cultivation Outdoor Cultivation Australia Legal Cannabis Market, By End Use: Industrial Use Medical Use Recreational Use Australia Legal Cannabis Market, By Region: Victoria & Tasmania Queensland Western Australia Northern Territory & Southern Australia Australia Capital Territory & New South Wales Key Attributes: Report Attribute Details No. of Pages 84 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $126.32 Million Forecasted Market Value (USD) by 2030 $420.33 Million Compound Annual Growth Rate 22.1% Regions Covered Australia For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Australian Legal Cannabis Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
